Kuhn E, Wu J, Karl J, Liao H, Zolg W, Guild B. Quantification of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C-labeled peptide standards. Proteomics. 2004;4(4):1175-1186.
Kuhn E, Addona T, Keshishian H, et al. Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin Chem. 2009;55(6):1108-1117.
Kuhn E, Whiteaker JR, Mani DR, et al. Interlaboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasma. Mol Cell Proteomics. 2012;11(6):M111.013854.
Ngo D, Sinha S, Shen D, Kuhn EW, et al. Aptamer-based proteomic profiling reveals novel candidate biomarkers and pathways in cardiovascular disease. Circulation. 2016;134(4):270-285.
Eric Kuhn, B.S.
Eric Kuhn is a research scientist II in the Proteomics Platform of the Broad Institute of MIT and Harvard, where he works under the direction of Steven A. Carr.
Kuhn is a hands-on expert in the development and application of peptide quantitation assays that utilize stable isotope standards, high-pressure liquid chromatography, and mass spectrometry. His research is focused on the design and implementation of automated multiplexed biochemical enrichment strategies that use antibodies and aptamers in combination with the high-throughput mass spectrometry to simultaneously quantify and characterize proteins in complex biological samples. These assays have been integral to the discovery of biomarkers in the areas of ovarian cancer, breast cancer, and cardiovascular disease research for over 10 years at the Broad Institute. He has also co-authored guidance documents for programs funded by the NIH that outline peptide standard specifications and targeted peptide measurement best practices.
Prior to joining the Broad Institute in 2005 as a senior biochemist, Kuhn worked in industry for Dupont NEN Products, AutoImmune Inc., and Millennium Pharmaceuticals. He moved into his current position in 2016.
Kuhn holds a B.S. in biochemistry from the University of New Hampshire.
Contact Eric Kuhn via email at firstname.lastname@example.org.